Technical advancement that is significant . But this is a long way from commercialisation and clinical proof of concept IMO >Management need to JV with a Health sciences Co
such as UBI ADO , Siemens NAN etc all cashed up and in the disease analysis field Ready to move into nano health as the next advancement .IMO Working biochip prior to FDA or like approval will need about 2/3 years of clinical trials and anywhere b/w $4m -$15M
expenditure A small cap like AXE does not have the luxury of time or money to develop product without the risk of being over taken by same but
different tech , commercialised by more aggressive Co. who may secure market share/dominance disregarding any issue of efficacy
because of its medical/ hospital industry track record.
AXE Price at posting:
$1.24 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)